vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and SEALED AIR CORP (SEE). Click either name above to swap in a different company.
SEALED AIR CORP is the larger business by last-quarter revenue ($1.4B vs $708.5M, roughly 2.0× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 3.1%, a 15.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 2.6%). SEALED AIR CORP produced more free cash flow last quarter ($257.7M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 2.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Sealed Air Corporation is a global provider of innovative packaging and protective solutions. Its core offerings include cushioning materials, food safety and preservation packaging, and sustainable waste-reducing packaging systems, serving retail, e-commerce, food and beverage, and industrial manufacturing markets worldwide.
MEDP vs SEE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.4B |
| Net Profit | $135.1M | $43.8M |
| Gross Margin | — | 28.6% |
| Operating Margin | 21.6% | 11.4% |
| Net Margin | 19.1% | 3.1% |
| Revenue YoY | 32.0% | 2.6% |
| Net Profit YoY | 15.5% | 700.0% |
| EPS (diluted) | $4.65 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.4B | ||
| Q3 25 | $659.9M | $1.3B | ||
| Q2 25 | $603.3M | $1.3B | ||
| Q1 25 | $558.6M | $1.3B | ||
| Q4 24 | $536.6M | $1.4B | ||
| Q3 24 | $533.3M | $1.3B | ||
| Q2 24 | $528.1M | $1.3B | ||
| Q1 24 | $511.0M | $1.3B |
| Q4 25 | $135.1M | $43.8M | ||
| Q3 25 | $111.1M | $255.1M | ||
| Q2 25 | $90.3M | $93.1M | ||
| Q1 25 | $114.6M | $113.5M | ||
| Q4 24 | $117.0M | $-7.3M | ||
| Q3 24 | $96.4M | $91.7M | ||
| Q2 24 | $88.4M | $98.3M | ||
| Q1 24 | $102.6M | $82.0M |
| Q4 25 | — | 28.6% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 30.7% | ||
| Q1 25 | — | 30.9% | ||
| Q4 24 | — | 30.0% | ||
| Q3 24 | — | 30.1% | ||
| Q2 24 | — | 31.2% | ||
| Q1 24 | — | 30.3% |
| Q4 25 | 21.6% | 11.4% | ||
| Q3 25 | 21.5% | 13.8% | ||
| Q2 25 | 20.9% | 15.0% | ||
| Q1 25 | 20.3% | 14.5% | ||
| Q4 24 | 23.4% | 11.7% | ||
| Q3 24 | 21.1% | 13.9% | ||
| Q2 24 | 19.9% | 15.4% | ||
| Q1 24 | 20.4% | 14.0% |
| Q4 25 | 19.1% | 3.1% | ||
| Q3 25 | 16.8% | 19.0% | ||
| Q2 25 | 15.0% | 7.0% | ||
| Q1 25 | 20.5% | 9.0% | ||
| Q4 24 | 21.8% | -0.5% | ||
| Q3 24 | 18.1% | 6.9% | ||
| Q2 24 | 16.7% | 7.4% | ||
| Q1 24 | 20.1% | 6.2% |
| Q4 25 | $4.65 | $0.30 | ||
| Q3 25 | $3.86 | $1.73 | ||
| Q2 25 | $3.10 | $0.63 | ||
| Q1 25 | $3.67 | $0.77 | ||
| Q4 24 | $3.67 | $-0.05 | ||
| Q3 24 | $3.01 | $0.63 | ||
| Q2 24 | $2.75 | $0.67 | ||
| Q1 24 | $3.20 | $0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $344.0M |
| Total DebtLower is stronger | — | $3.3B |
| Stockholders' EquityBook value | $459.1M | $1.2B |
| Total Assets | $2.0B | $7.0B |
| Debt / EquityLower = less leverage | — | 2.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $344.0M | ||
| Q3 25 | $285.4M | $282.5M | ||
| Q2 25 | $46.3M | $354.4M | ||
| Q1 25 | $441.4M | $335.2M | ||
| Q4 24 | $669.4M | $371.8M | ||
| Q3 24 | $656.9M | $386.0M | ||
| Q2 24 | $510.9M | $388.6M | ||
| Q1 24 | $407.0M | $352.8M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $4.2B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $459.1M | $1.2B | ||
| Q3 25 | $293.6M | $1.2B | ||
| Q2 25 | $172.4M | $953.1M | ||
| Q1 25 | $593.6M | $797.9M | ||
| Q4 24 | $825.5M | $624.5M | ||
| Q3 24 | $881.4M | $771.2M | ||
| Q2 24 | $763.6M | $650.1M | ||
| Q1 24 | $671.5M | $598.3M |
| Q4 25 | $2.0B | $7.0B | ||
| Q3 25 | $1.8B | $7.1B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.9B | $7.0B | ||
| Q4 24 | $2.1B | $7.0B | ||
| Q3 24 | $2.1B | $7.3B | ||
| Q2 24 | $1.9B | $7.3B | ||
| Q1 24 | $1.8B | $7.2B |
| Q4 25 | — | 2.65× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | 4.18× | ||
| Q1 25 | — | 5.26× | ||
| Q4 24 | — | 6.72× | ||
| Q3 24 | — | 5.62× | ||
| Q2 24 | — | 6.81× | ||
| Q1 24 | — | 7.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $293.6M |
| Free Cash FlowOCF − Capex | $188.1M | $257.7M |
| FCF MarginFCF / Revenue | 26.6% | 18.5% |
| Capex IntensityCapex / Revenue | 0.6% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.43× | 6.70× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $458.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $293.6M | ||
| Q3 25 | $246.2M | $165.9M | ||
| Q2 25 | $148.5M | $136.6M | ||
| Q1 25 | $125.8M | $31.9M | ||
| Q4 24 | $190.7M | $244.2M | ||
| Q3 24 | $149.1M | $170.5M | ||
| Q2 24 | $116.4M | $188.2M | ||
| Q1 24 | $152.7M | $125.1M |
| Q4 25 | $188.1M | $257.7M | ||
| Q3 25 | $235.5M | $119.6M | ||
| Q2 25 | $142.4M | $93.2M | ||
| Q1 25 | $115.8M | $-12.0M | ||
| Q4 24 | $183.0M | $185.1M | ||
| Q3 24 | $138.5M | $115.2M | ||
| Q2 24 | $103.5M | $129.5M | ||
| Q1 24 | $147.2M | $78.0M |
| Q4 25 | 26.6% | 18.5% | ||
| Q3 25 | 35.7% | 8.9% | ||
| Q2 25 | 23.6% | 7.0% | ||
| Q1 25 | 20.7% | -0.9% | ||
| Q4 24 | 34.1% | 13.6% | ||
| Q3 24 | 26.0% | 8.6% | ||
| Q2 24 | 19.6% | 9.7% | ||
| Q1 24 | 28.8% | 5.9% |
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 1.6% | 3.4% | ||
| Q2 25 | 1.0% | 3.3% | ||
| Q1 25 | 1.8% | 3.5% | ||
| Q4 24 | 1.4% | 4.4% | ||
| Q3 24 | 2.0% | 4.1% | ||
| Q2 24 | 2.4% | 4.4% | ||
| Q1 24 | 1.1% | 3.6% |
| Q4 25 | 1.43× | 6.70× | ||
| Q3 25 | 2.22× | 0.65× | ||
| Q2 25 | 1.65× | 1.47× | ||
| Q1 25 | 1.10× | 0.28× | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | 1.86× | ||
| Q2 24 | 1.32× | 1.91× | ||
| Q1 24 | 1.49× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SEE
| Protective Segment | $1.1B | 78% |
| Other | $292.0M | 21% |
| Pension Plans Defined Benefit | $7.9M | 1% |
